StocksMedium•7 October 2026•
1 min read
FDA Approves Pfizer's TUKYSA for Front-Line Breast Cancer Maintenance
Key Facts
1The U.S. FDA approved Pfizer's TUKYSA in combination with other therapies for the front-line maintenance treatment of HER2+ metastatic breast cancer.
The U.S. FDA approved Pfizer's TUKYSA in combination with other therapies for the front-line maintenance treatment of HER2+ metastatic breast cancer. Business Wire reported that the approval allows the drug to be used for adults with metastatic disease following induction treatment, providing a new chemotherapy-free maintenance option.
PFE closed at $27.5 on October 6, 2026, ahead of this regulatory expansion. The decision marks a significant milestone for Pfizer's oncology portfolio, as it expands the addressable market for a key asset within the healthcare sector.